JP2020533301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533301A5 JP2020533301A5 JP2020513648A JP2020513648A JP2020533301A5 JP 2020533301 A5 JP2020533301 A5 JP 2020533301A5 JP 2020513648 A JP2020513648 A JP 2020513648A JP 2020513648 A JP2020513648 A JP 2020513648A JP 2020533301 A5 JP2020533301 A5 JP 2020533301A5
- Authority
- JP
- Japan
- Prior art keywords
- variant polypeptide
- composition
- mutated
- composition according
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023133442A JP2023157959A (ja) | 2017-09-06 | 2023-08-18 | インターロイキン－１８バリアントとその利用法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762554605P | 2017-09-06 | 2017-09-06 | |
| US62/554,605 | 2017-09-06 | ||
| US201862652279P | 2018-04-03 | 2018-04-03 | |
| US62/652,279 | 2018-04-03 | ||
| PCT/US2018/049648 WO2019051015A1 (en) | 2017-09-06 | 2018-09-06 | VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133442A Division JP2023157959A (ja) | 2017-09-06 | 2023-08-18 | インターロイキン－１８バリアントとその利用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533301A JP2020533301A (ja) | 2020-11-19 |
| JP2020533301A5 true JP2020533301A5 (cg-RX-API-DMAC10.html) | 2021-10-14 |
| JP7795181B2 JP7795181B2 (ja) | 2026-01-07 |
Family
ID=65517760
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513648A Active JP7795181B2 (ja) | 2017-09-06 | 2018-09-06 | インターロイキン－１８バリアントとその利用法 |
| JP2023133442A Pending JP2023157959A (ja) | 2017-09-06 | 2023-08-18 | インターロイキン－１８バリアントとその利用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133442A Pending JP2023157959A (ja) | 2017-09-06 | 2023-08-18 | インターロイキン－１８バリアントとその利用法 |
Country Status (13)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12029778B2 (en) | 2019-05-13 | 2024-07-09 | Yale University | Interleukin-18 mimics and methods of use |
| KR20230009430A (ko) * | 2020-05-12 | 2023-01-17 | 리제너론 파아마슈티컬스, 인크. | 신규 il10 효능제 및 그의 사용 방법 |
| CN116368148A (zh) * | 2020-08-19 | 2023-06-30 | 明峰治疗股份公司 | 修饰的il-18多肽及其用途 |
| KR20230117120A (ko) * | 2020-11-02 | 2023-08-07 | 심카 아이엘-18, 인크. | 인터류킨-18 변이체 및 사용 방법 |
| CN116848130A (zh) * | 2021-02-10 | 2023-10-03 | 国立大学法人长崎大学 | 新型人白细胞介素-18突变体及其用途 |
| WO2023010021A1 (en) | 2021-07-27 | 2023-02-02 | Xencor, Inc. | Il-18-fc fusion proteins |
| JP7849832B2 (ja) | 2021-08-06 | 2026-04-22 | 国立大学法人 長崎大学 | がんの治療剤 |
| JP2024546930A (ja) * | 2021-12-15 | 2024-12-26 | ジェネンテック， インコーポレイテッド | 安定化ｉｌ－１８ポリペプチド及びその使用 |
| WO2023118497A1 (en) * | 2021-12-22 | 2023-06-29 | Pieris Pharmaceuticals Gmbh | Novel il-18 variants |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| CA3244053A1 (en) * | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | MODIFIED IL-18 POLYPEPTIDES |
| US20230263831A1 (en) * | 2022-02-23 | 2023-08-24 | Fred Hutchinson Cancer Center | Methods for enhancing anti-tumor activity of exhausted t cells |
| CA3259975A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| WO2023215834A1 (en) * | 2022-05-05 | 2023-11-09 | Hospital Espanol Auxilio Mutuo De Puerto Rico, Inc. | Methods for treating bladder cancer |
| CN120051292A (zh) * | 2022-08-05 | 2025-05-27 | 融合生物疗法公司 | Il-18融合蛋白以及生产il-18的方法 |
| WO2024044780A1 (en) * | 2022-08-26 | 2024-02-29 | Sutro Biopharma, Inc. | Interleukin-18 variants and uses thereof |
| EP4584287A1 (en) * | 2022-09-06 | 2025-07-16 | TJ Biopharma (Shanghai) Co., Ltd. | Il-18 variant polypeptides |
| AU2023364731A1 (en) * | 2022-10-21 | 2025-04-03 | Diagonal Therapeutics Inc. | Heteromeric agonistic antibodies to il-18 receptor |
| WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
| US20260151445A1 (en) | 2022-12-07 | 2026-06-04 | Guangzhou Virotech Pharmaceutical Co., Ltd. | Use of dr-18 and oncolytic vaccinia virus in preparation of anti-tumor drug |
| EP4646433A1 (en) | 2023-01-06 | 2025-11-12 | Lassen Therapeutics, Inc. | Anti-il-18bp antibodies |
| TW202430560A (zh) * | 2023-01-06 | 2024-08-01 | 美商拉森醫療公司 | 抗ｉｌ－１８ｂｐ抗體 |
| JP2026503002A (ja) * | 2023-01-06 | 2026-01-27 | アレクトル エルエルシー | 抗ｉｌ１８結合タンパク質抗体及びその使用方法 |
| IL322211A (en) * | 2023-01-24 | 2025-09-01 | Msd Int Business Gmbh | Methods and preparations for combined therapy |
| CN121666402A (zh) * | 2023-06-09 | 2026-03-13 | 默克专利股份公司 | Il-18模拟物 |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025015103A1 (en) * | 2023-07-10 | 2025-01-16 | The Children's Hospital Of Philadelphia | Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology |
| US20250188166A1 (en) | 2023-08-23 | 2025-06-12 | Bright Peak Therapeutics Ag | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof |
| US20250186597A1 (en) | 2023-08-23 | 2025-06-12 | Bright Peak Therapeutics Ag | Targeted immune activation with il-18 immunocytokines |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025068413A1 (en) | 2023-09-28 | 2025-04-03 | Prokarium Limited | Interleukin 18 variants |
| WO2025085447A1 (en) | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Pd-1 targeted il18-fc fusion proteins |
| CN120093897A (zh) | 2023-12-04 | 2025-06-06 | 广州威溶特医药科技有限公司 | Dr-18和单纯疱疹病毒在制备抗肿瘤药物中的应用 |
| CN120189493A (zh) | 2023-12-22 | 2025-06-24 | 广州威溶特医药科技有限公司 | Dr-18和m1病毒在制备抗肿瘤药物中的应用 |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
| WO2025151273A1 (en) * | 2024-01-08 | 2025-07-17 | Adimab, Llc | Il-18 polypeptides and uses thereof |
| WO2025185694A1 (en) * | 2024-03-06 | 2025-09-12 | TJ Biopharma (Shanghai) Co., Ltd. | Constructs comprising il-18 components and uses thereof |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025251226A1 (en) | 2024-06-05 | 2025-12-11 | Nuwacell Biotechnologies Co., Ltd. | Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| CN119798405B (zh) * | 2024-12-30 | 2026-06-30 | 华润生物医药有限公司 | Il-21的突变体及其制备方法和应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US5190931A (en) | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| EP1669454A3 (en) * | 1996-06-27 | 2009-04-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma |
| US6790442B1 (en) | 1996-06-27 | 2004-09-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ |
| JP4024366B2 (ja) | 1996-11-29 | 2007-12-19 | 株式会社林原生物化学研究所 | ポリペプチド |
| JP3955352B2 (ja) * | 1997-02-25 | 2007-08-08 | 株式会社林原生物化学研究所 | 破骨細胞形成阻害剤 |
| TWI227136B (en) * | 1998-05-21 | 2005-02-01 | Smithkline Beecham Corp | Novel pharmaceutical composition for the prevention and/or treatment of cancer |
| JP2001266941A (ja) | 2000-03-17 | 2001-09-28 | Sony Corp | ゲル電解質電池の製造方法 |
| AU2001275166B2 (en) * | 2000-06-02 | 2005-07-28 | Smithkline Beecham Corporation | Methods of treating viral diseases with il-18 and il-18 combinations |
| PL208592B1 (pl) | 2000-06-15 | 2011-05-31 | Smithkline Beecham Corp | Sposób wytwarzania aktywnego ludzkiego polipeptydu IL-18 z ludzkiego polipeptydu prekursora IL-18 |
| US6818444B2 (en) | 2000-08-04 | 2004-11-16 | Heska Corporation | Canine and feline proteins, nucleic acid molecules and uses thereof |
| JP2004530432A (ja) | 2001-03-08 | 2004-10-07 | アレス・トレーディング・ソシエテ・アノニム | インターロイキン−１８変異体、その産生および使用 |
| AU2002257243A1 (en) | 2001-05-04 | 2002-11-18 | Cornell Research Foundation, Inc. | Rapidly cleavable sumo fusion protein expression system for difficult to express proteins |
| AU2002326961A1 (en) | 2001-10-10 | 2003-04-22 | Centocor, Inc. | Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid |
| AU2002365269A1 (en) | 2001-10-26 | 2003-07-24 | Centocor, Inc. | Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses |
| US6800479B2 (en) | 2001-12-11 | 2004-10-05 | Samyang Genex Corporation | Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them |
| DE60318014T2 (de) | 2002-01-07 | 2008-11-27 | Lifesensors, Inc. | Verfahren und zusammensetzungen für die proteinexpression und reinigung |
| US7220576B2 (en) | 2002-01-07 | 2007-05-22 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
| US7253260B2 (en) | 2002-04-17 | 2007-08-07 | Smithkline Beecham Corporation | Human IL-18 crystal structure |
| US20050153880A1 (en) * | 2002-06-27 | 2005-07-14 | Yukio Goto | Methods of treating or preventing ibd with il-18 |
| BR0315155A (pt) * | 2002-10-08 | 2005-08-16 | Ares Trading Sa | Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina |
| EP1613274B1 (en) * | 2003-04-15 | 2010-03-03 | GlaxoSmithKline LLC | Human il-18 substitution mutants and their conjugates |
| AU2004238524B2 (en) * | 2003-05-13 | 2011-06-23 | Merck Serono Sa | Active variants of the IL-18 binding protein and medical uses thereof |
| AU2004254600A1 (en) | 2003-06-26 | 2005-01-13 | Lifesensors, Inc. | Methods and compositions for enhanced protein expression and purification |
| ES2356154T3 (es) * | 2003-07-21 | 2011-04-05 | Transgene S.A. | Citoquinas multifuncionales. |
| DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| WO2005075648A1 (en) * | 2004-01-28 | 2005-08-18 | Gifu University | Interleukin-18 mutant proteins |
| ATE526057T1 (de) | 2004-08-20 | 2011-10-15 | Glaxosmithkline Llc | Wundheilung durch verabreichung von menschlichem il-18 |
| EP1836214A4 (en) | 2004-12-30 | 2009-01-21 | Lifesensors Inc | COMPOSITIONS, METHODS, AND KITS FOR IMPROVING PROTEIN EXPRESSION, SOLUBILITY, AND ISOLATION |
| US20100061958A1 (en) | 2006-09-14 | 2010-03-11 | The Trustees Of The University Of Pennsylvania | Modulation of Regulatory T Cells by Human IL-18 |
| CA2674304C (en) | 2006-12-29 | 2016-02-23 | Lifesensors, Inc. | Methods and compositions for enhanced protein expression and purification |
| US20090202475A1 (en) | 2007-11-07 | 2009-08-13 | Genentech, Inc. | Compositions and methods for treatment of microbial disorders |
| CN101960209B (zh) | 2008-02-27 | 2012-11-07 | 夏普株式会社 | 照明装置、显示装置和电视接收装置 |
| TW200951219A (en) | 2008-05-06 | 2009-12-16 | Academia Sinica | An improved SUMO fusion protein system for effective production of native proteins |
| CN101993495B (zh) | 2009-08-12 | 2013-07-24 | 上海近岸科技有限公司 | 一种蛋白质混合物及其制备方法 |
| US9316417B2 (en) | 2012-06-29 | 2016-04-19 | Sunpower Corporation | Framing system for mounting solar collecting devices |
| SG11201408530YA (en) | 2012-08-02 | 2015-03-30 | Hoffmann La Roche | Method for producing monomeric and multimeric molecules and uses thereof |
| US9376489B2 (en) * | 2012-09-07 | 2016-06-28 | Novartis Ag | IL-18 binding molecules |
| US10646548B2 (en) | 2013-10-08 | 2020-05-12 | Georgia State University Research Foundation, Inc. | Compositions including IL-18 and IL-22 and their use in anti-viral therapies |
| CN107660150B (zh) | 2015-03-05 | 2023-10-24 | Ab2生物股份有限公司 | Il-18结合蛋白(il-18bp)和抗体在炎性疾病中 |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| US11053293B2 (en) | 2016-02-05 | 2021-07-06 | Washington University | Compositions and methods for targeted cytokine delivery |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| ITUA20161992A1 (it) | 2016-03-24 | 2017-09-24 | Plico Biotech Inc | Sumo e suoi utilizzi |
| EP3493827A4 (en) | 2016-08-04 | 2020-02-26 | Memorial Sloan-Kettering Cancer Center | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY |
| AU2017337073A1 (en) | 2016-09-30 | 2019-04-18 | Baylor College Of Medicine | Antibody based gene therapy with tissue-directed expression |
| TWI591177B (zh) | 2016-10-27 | 2017-07-11 | 中化合成生技股份有限公司 | 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法 |
| KR102625293B1 (ko) | 2017-03-06 | 2024-01-15 | 알토 바이오사이언스 엘엘씨 | Il-12 및 il-18로의 il-15-기반 융합 |
| US20200306301A1 (en) | 2017-07-03 | 2020-10-01 | Torque Therapeutics, Inc. | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof |
| WO2019213528A1 (en) | 2018-05-04 | 2019-11-07 | Sigma-Aldrich Co. Llc | Producing recombinant proteins with reduced levels of host cell proteins |
| CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
| CA3109139A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2020047333A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| CA3125556A1 (en) | 2019-01-04 | 2020-07-09 | Repertoire Immune Medicines, Inc. | Methods of producing high diversity peptide libraries and promoting protein folding |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| EP3976068A4 (en) | 2019-05-31 | 2023-08-09 | Children's National Medical Center | CYTOKIN COCKTAILS FOR SELECTIVE EXPANSION OF T-CELL SUBSETS |
| CN114555791B (zh) | 2019-08-13 | 2026-07-14 | 伦敦国王学院 | Il-1超家族时空限制性活性细胞因子铠装的免疫应答细胞 |
| US20220363766A1 (en) | 2019-10-09 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cytotoxic t cell resistant tumors |
| KR20230084470A (ko) | 2020-08-14 | 2023-06-13 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| CN116368148A (zh) | 2020-08-19 | 2023-06-30 | 明峰治疗股份公司 | 修饰的il-18多肽及其用途 |
| KR20230117120A (ko) | 2020-11-02 | 2023-08-07 | 심카 아이엘-18, 인크. | 인터류킨-18 변이체 및 사용 방법 |
| WO2022229412A1 (en) | 2021-04-30 | 2022-11-03 | Cellectis S.A. | New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy |
| WO2022260968A1 (en) | 2021-06-10 | 2022-12-15 | Chimera Bioengineering, Inc. | Compositions and methods for activating natural killer cells |
-
2018
- 2018-09-06 JP JP2020513648A patent/JP7795181B2/ja active Active
- 2018-09-06 IL IL272635A patent/IL272635B2/en unknown
- 2018-09-06 BR BR112020004389-3A patent/BR112020004389A2/pt active Search and Examination
- 2018-09-06 EP EP18853870.6A patent/EP3678681A4/en active Pending
- 2018-09-06 CN CN201880071694.4A patent/CN111315395A/zh active Pending
- 2018-09-06 SG SG11202001384TA patent/SG11202001384TA/en unknown
- 2018-09-06 KR KR1020207009724A patent/KR20200066623A/ko not_active Ceased
- 2018-09-06 AU AU2018330444A patent/AU2018330444B2/en active Active
- 2018-09-06 IL IL305370A patent/IL305370A/en unknown
- 2018-09-06 US US16/123,063 patent/US20190070262A1/en not_active Abandoned
- 2018-09-06 WO PCT/US2018/049648 patent/WO2019051015A1/en not_active Ceased
- 2018-09-06 MX MX2020002542A patent/MX2020002542A/es unknown
- 2018-09-06 CA CA3080492A patent/CA3080492A1/en active Pending
-
2022
- 2022-11-15 US US18/055,581 patent/US12343379B2/en active Active
-
2023
- 2023-01-20 US US18/157,385 patent/US12685759B2/en active Active
- 2023-03-08 US US18/180,389 patent/US12403180B2/en active Active
- 2023-07-19 ZA ZA2023/07212A patent/ZA202307212B/en unknown
- 2023-08-18 JP JP2023133442A patent/JP2023157959A/ja active Pending
- 2023-11-15 AU AU2023266285A patent/AU2023266285A1/en not_active Abandoned
-
2024
- 2024-04-04 US US18/626,930 patent/US20240325494A1/en active Pending
- 2024-11-08 US US18/941,441 patent/US12594325B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023550545A5 (cg-RX-API-DMAC10.html) | ||
| JP7744479B2 (ja) | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 | |
| JP7223822B2 (ja) | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 | |
| US12312391B2 (en) | Anti-mutated KRAS T cell receptors | |
| Klein et al. | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines | |
| Hahn et al. | The future of immune checkpoint cancer therapy after PD-1 and CTLA-4 | |
| GB2617483A (en) | Interleukin-18 variants and methods of use | |
| CN113784976B (zh) | 用于鉴定抗原特异性t细胞的组合物和方法 | |
| TWI905347B (zh) | 用於調變ｃａｒ－ｔ活性之方法與組成物 | |
| JP2020508691A (ja) | Ｉｌ−１２及びｉｌ−１８へのｉｌ−１５系融合 | |
| CN107881183A (zh) | 鼠抗‑ny‑eso‑1 t细胞受体 | |
| CN111601817A (zh) | 分泌il-33的免疫应答细胞及其用途 | |
| WO2020152161A1 (en) | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy | |
| CN114980907A (zh) | 增强细胞癌症治疗的t细胞死亡相关基因8(tdag8)调节 | |
| AU2024312524A1 (en) | Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains | |
| JP2020535832A (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 | |
| US20250302953A1 (en) | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells | |
| WO2024123975A2 (en) | A t cell receptor recognizing an unmutated foxm1 epitope presented on hla-a*02:01 | |
| EP4157863A2 (en) | Engineered immune cells, compositions and methods thereof | |
| CN115279389A (zh) | 新型显性负性Fas多肽、包含其的细胞及其用途 | |
| US20240424098A1 (en) | Modified immune cells and methods of use thereof | |
| CN120758457A (zh) | 改造的免疫细胞、靶向Mettl13基因的gRNA和应用 | |
| CA2968399C (en) | Anti-mutated kras t cell receptors | |
| CN118541394A (zh) | 分泌team的抗间皮素car t细胞及其使用方法 | |
| Khana et al. | Application of CAR T cells for |